'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Dr Reddys Laboratories has increased 19.89% to Rs 8528.4 crore. Sales of Pharmaceutical Services segment has gone up 1.29% to Rs 1,167.50 crore (accounting for 13.39% of total sales). Sales of Global Generics segment has gone up 23.16% to Rs 7,536.50 crore (accounting for 86.46% of total sales). Sales of Others segment has gone down 90.70% to Rs 13.20 crore (accounting for 0.15% of total sales). Inter-segment sales came down from Rs 330.70 crore to Rs 211.20 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 13.93% to Rs 4,726.30 crore. PBIT of Pharmaceutical Services segment rose 7.15% to Rs 251.80 crore (accounting for 5.33% of total PBIT). PBIT of Global Generics segment rose 17.86% to Rs 4,470.70 crore (accoun...
Pleaselogin & subscribe to view the full report.
More Reports
|
|